Skip to main content
Japanese Journal of Comprehensive Rehabilitation Science logoLink to Japanese Journal of Comprehensive Rehabilitation Science
. 2026 Nov 5;17:68–76. doi: 10.11336/jjcrs.17.68

Infection Risk Factors and Immunological Parameters in Patients with Spinal Cord Injury

Katsuma Tani 1,2, Ryo Inagaki 3, Kohei Tomita 3, Aya Ozaki 3, Yasutoshi Iwai 3, Miwa Hayata 3, Atsushi Ikeda 3, Takanori Namba 3, Kazunari Furusawa 3, Ryota Chijimatsu 4, Daisuke Ennishi 5, Tomofumi Yano 6
PMCID: PMC13771521  PMID: 43041768

Abstract

Tani K, Inagaki R, Tomita K, Ozaki A, Iwai Y, Hayata M, Ikeda A, Namba T, Furusawa K, Chijimatsu R, Ennishi D, Yano T. Infection Risk Factors and Immunological Parameters in Patients with Spinal Cord Injury. Jpn J Compr Rehabil Sci 2026; 17: 68-76.

Objective

Infectious diseases are a major cause of death in patients with spinal cord injury (SCI), and SCI-induced immune deficiency syndrome has been suggested to contribute to susceptibility to infection. Based on the hypothesis that the neurological level of injury and injury severity are associated with infection risk, we investigated factors associated with infection in patients with SCI.

Methods

We conducted a retrospective observational study of 362 hospitalization episodes in 129 patients with SCI admitted between 2016 and 2024. We analyzed the associations between infection and the neurological level of injury, American Spinal Injury Association Impairment Scale (AIS) grade, age, sex, time since SCI, body mass index (BMI), and other clinical factors. We used multivariable analysis with generalized estimating equations (GEE) to account for within-patient correlations from repeated hospitalizations. In the prospective analysis, we evaluated lymphocyte subsets, interferon-γ (IFN-γ), and interleukin-6 (IL-6) across nine episodes in seven patients.

Results

The frequency of infection did not differ significantly between the cervical and thoracolumbar SCI groups; however, it was significantly higher in the AIS A group than in the AIS B-D group. In analyses stratified by AIS, the frequency of infection did not differ significantly between cervical and thoracolumbar SCI in either the AIS A or AIS B-D group. In the multivariable GEE analysis, a longer time since SCI was significantly associated with lower odds of infection (OR 0.78 per 1-year increase, 95% CI 0.66-0.91, p = 0.0022), whereas AIS grade, neurological level of injury, age ≥65 years, sex, and low BMI were not significantly associated with infection. In the prospective analysis, some T-cell-related parameters tended to decrease during infection.

Conclusions

Infection risk in patients with SCI was associated with time since injury, and a longer time since SCI was associated with lower odds of infection. In contrast, the neurological level of injury and injury severity were not independently associated with infection in the multivariable analysis.

Keywords: spinal cord injury, infection, American Spinal Injury Association Impairment Scale, SCI-induced immune deficiency syndrome

Introduction

The life expectancy of patients with spinal cord injury (SCI) remains shorter than that of the general population, and infectious diseases continue to be a major cause of death [1, 2]. According to a nationwide study using the spinal cord injury database of Rosai Hospitals in Japan, the leading causes of death in patients with SCI were pneumonia (21.2%), malignant neoplasms (17.8%), and sepsis (10.6%). The same study reported that the standardized mortality ratio, an indicator of mortality risk compared to the general population, was extremely high for patients with sepsis (146.2) [3]. These findings indicate that infectious diseases are an important clinical issue in patients with SCI, in terms of both the frequency and risk of severe outcomes.

Several mechanisms directly increase the risk of infection in patients with SCI. For example, dysphagia and impaired sputum clearance associated with a high cervical SCI can directly increase the risk of pneumonia. Neurogenic bladder due to SCI can also increase the risk of urinary tract infection. In addition, paralysis-related pressure ulcers increase the risk of skin and soft-tissue infections [4]. However, vulnerability to infection in patients with SCI cannot be fully explained by physical impairment alone. In vivo studies using mouse models of SCI have shown that antiviral immune responses against mouse hepatitis virus and influenza virus are impaired after SCI [5, 6]. These findings suggest that SCI affects not only motor and sensory functions below the level of injury, but also systemic immune responses.

In recent years, the coexistence of immunosuppression and chronic inflammation after SCI has attracted attention as SCI-induced immune deficiency syndrome (SCI-IDS). The proposed mechanisms underlying SCI-IDS include abnormalities in the sympathetic nervous and neuroendocrine systems, splenic atrophy, changes in lymphocyte count and function, and abnormal bone marrow hematopoiesis [7]. In a mouse model of SCI, chronic dysfunction of the bone marrow, accompanied by excessive proliferation and retention of hematopoietic stem and progenitor cells there, has also been reported [8]. These findings suggest that SCI is a systemic disease, rather than a disorder limited to motor and sensory dysfunction below the level of injury. However, the clinical significance of SCI-IDS remains insufficiently understood, and no infection prevention strategies or therapeutic interventions targeting SCI-IDS have been established [7, 9].

Previous studies of peripheral blood in patients with SCI have reported elevated levels of inflammatory cytokines and C-reactive protein, as well as changes in lymphocyte counts and subsets [10, 11, 12, 13, 14]. However, these findings are not consistent across studies. Clinical factors such as the neurological level of injury, injury severity, time since SCI, infection status, pressure ulcers, and neuropathic pain may contribute to these inconsistencies. Based on the concept of SCI-IDS, the neurological level of injury and injury severity may influence immune dysfunction and infection risk through differences in the degree of sympathetic nervous system and neuroendocrine dysfunction [7]. However, whether the neurological level of injury and injury severity are associated with infection risk in patients with SCI in Japan has not been sufficiently investigated.

This study aimed to identify the factors associated with infection in patients with SCI and explore changes in immunological parameters. Based on the SCI-IDS concept, we hypothesized that the neurological level of injury and injury severity are associated with the risk of infection. Therefore, we retrospectively investigated the associations between clinical factors, including the neurological level of injury, injury severity, time since SCI, and infection. In addition, we conducted an exploratory evaluation of the changes in lymphocyte subsets and serum cytokines through prospective immunological analysis.

Methods

1. Study design and participants

This single-center observational study included patients with spinal cord injury (SCI) and comprised retrospective and prospective immunological analyses. The retrospective analysis included 362 hospitalization episodes in 129 patients with SCI who were admitted between 2016 and 2024, for whom the neurological level of injury, injury severity, and the presence or absence of infection were confirmed from medical records. The prospective immunological analysis included nine episodes in seven patients with SCI who were admitted between 2024 and 2025 and provided written informed consent. Episodes with missing data that were required for the analysis, and those judged inappropriate by the principal investigator or co-investigators, were excluded. Rehabilitation specialists assessed the neurological level and severity of injury based on the International Standards for Neurological Classification of Spinal Cord Injury [15].

The primary outcome of this retrospective analysis was the presence or absence of infection. Infection episodes were defined as those diagnosed by the attending physician as bacterial infections and treated with antimicrobial agents for therapeutic purposes. We excluded episodes with viral infections, including COVID-19, and those managed with symptomatic treatment alone. We collected data on the clinical factors potentially associated with infection, including the neurological level of injury, injury severity, age, sex, time since SCI, and body mass index (BMI), from medical records. We defined low BMI as a BMI <18.5 kg/m2. Analyses were performed at the hospitalization episode level. The neurological level of injury was classified as cervical SCI or thoracolumbar SCI, and injury severity was classified as AIS A or AIS B-D. To avoid the influence of infection-related reactive changes, we evaluated the white blood cell (WBC) count, neutrophil count, lymphocyte count, and C-reactive protein (CRP) level using admission data from the first non-infectious episode for each patient.

In the prospective immunological analysis, we measured lymphocyte subsets, interferon-γ (IFN-γ), and interleukin-6 (IL-6) using peripheral blood samples. BML, Inc. performed lymphocyte subset analysis using flow cytometry. T cells, effector T cells, effector cytotoxic T cells (effector Tc cells), effector helper T cells (effector Th cells), regulatory T cells (Tregs), B cells, and natural killer (NK) cells were evaluated. In two patients with both non-infectious and infectious episodes, we compared changes in immunological parameters within each patient as an exploratory analysis.

2. Statistical analysis

Continuous variables were presented as medians (interquartile ranges), whereas categorical variables were presented as numbers (%). All p values were two-sided, and p < 0.05 was considered statistically significant. Continuous variables were compared between the two groups using the Mann-Whitney U test, and categorical variables were compared using Fisher's exact test. We evaluated the correlations between time since SCI and WBC, neutrophil, and lymphocyte counts using Spearman's rank correlation coefficient (ρ) based on data from the first non-infectious episode for each patient.

To assess the potential influence of repeated hospitalizations on the analysis, we examined the association between a history of infection and the total number of hospitalizations on a per-patient basis using the Mann-Whitney U test. In addition, the analyses were stratified by injury severity, and the frequency of infection was compared between the cervical and thoracolumbar SCI groups within the AIS A and AIS B-D groups using Fisher's exact test.

To identify factors associated with infection while accounting for within-patient correlations from repeated hospitalizations, we performed a multivariable analysis using generalized estimating equations (GEE), with infection status as the dependent variable and patient ID as the clustering variable. Age was categorized as <65 or ≥65 years. We included neurological level of injury, injury severity, age ≥65 years, sex, time since SCI (per 1-year increase), and low BMI as covariates. Statistical analyses were performed using EZR, a graphical user interface for R Commander [16], and GEE analyses were performed using the geepack package in R.

3. Ethics approval

This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects and was approved by the Ethics Committee of the Japan Organization of Occupational Health and Safety (approval number: JPJOHAS2024FH03). For the retrospective analysis, information about the study was disclosed and participants were given the opportunity to opt out of participation. Written informed consent was obtained from all participants for the prospective immunological analysis.

Results

1. Baseline characteristics

During the study period, we screened 403 hospitalization episodes in 164 patients with SCI. After excluding 41 episodes in 35 patients with missing data, 362 episodes in 129 patients were included in the final analysis. When the episodes were classified according to the neurological level of injury, 187 and 175 episodes were classified as cervical and thoracolumbar SCI, respectively.

The cervical SCI group had a higher median age and longer time since SCI than the thoracolumbar SCI group. The distribution of injury severity differed significantly between the two groups, with a higher proportion of AIS A in the thoracolumbar SCI group (p < 0.001). In contrast, sex, BMI, and the proportion of patients with a low BMI did not differ significantly between the two groups (Table 1). When episodes were classified according to injury severity, 283 episodes were classified as AIS A and 79 as AIS B-D. The AIS A group had a lower median age and a higher proportion of male patients than the AIS B-D group. In contrast, the groups did not differ significantly in terms of time since SCI, BMI, or proportion of patients with a low BMI (Table 2).

Table 1.

Characteristics of hospitalization episodes according to neurological level of injury.

Cervical (N = 187) Thoracolumbar (N = 175) p value
Age, years 59 (45-69) 48 (28-58) <0.001
Sex, No. (%)
 Male 166 (89) 153 (87)
 Female 21 (11) 22 (13) 0.75
AIS grade, No. (%)
 A 120 (64) 163 (93)
 B-D 67 (36) 12 (7) <0.001
Time from SCI (days) 294 (171-686) 210 (119-411) <0.001
BMI (kg/m2) 21.5 (19.0-23.6) 21.1 (18.9-24.1) 0.83
Low BMI, No. (%) <18.5 kg/m2 39 (21) 37 (21) 1.00

Data are presented as median (interquartile range) or number (percentage). AIS, American Spinal Injury Association Impairment Scale; BMI, body mass index; SCI, spinal cord injury.

Table 2.

Characteristics of hospitalization episodes according to injury severity.

AIS A (N = 283) AIS B-D (N = 79) p value
Age, years 51 (34-62) 63 (41-72) <0.001
Sex, No. (%)
 Male 263 (93) 56 (71)
 Female 20 (7) 23 (29) <0.001
Time from SCI (days) 240 (133-489) 273 (170-696) 0.19
BMI (kg/m2) 21.1 (18.9-24.0) 22.0 (19.6-23.6) 0.31
Low BMI, No. (%) <18.5 kg/m2 63 (22) 13 (16) 0.35

Data are presented as median (interquartile range) or number (percentage). AIS, American Spinal Injury Association Impairment Scale; BMI, body mass index; SCI, spinal cord injury.

2. Laboratory findings during non-infectious episodes

Laboratory findings were compared using data from the first non-infectious episode for each patient. In the comparison according to neurological level of injury, lymphocyte count was significantly higher in the cervical SCI group than in the thoracolumbar SCI group. In contrast, there were no significant differences in the WBC count, neutrophil count, or CRP level. In the comparison according to injury severity, there were no significant differences in WBC count, neutrophil count, lymphocyte count, or CRP level between the AIS A group and AIS B-D group (Table 3). In addition, no significant correlations were observed between time since SCI and WBC count, neutrophil count, or lymphocyte count during non-infectious episodes (WBC count: ρ = -0.024, p = 0.74; neutrophil count: ρ = -0.043, p = 0.54; lymphocyte count: ρ = 0.130, p = 0.066).

Table 3.

Laboratory findings during non-infectious episodes according to neurological level of injury and injury severity.

Cervical (N = 66) Thoracolumbar (N = 63) p value
WBC (/μL) 6150 (4900-7130) 5800 (4700-6850) 0.45
Neutrophil (/μL) 3400 (2500-4110) 3530 (2540-4190) 0.86
Lymphocyte (/μL) 1930 (1470-2220) 1660 (1430-1960) 0.02
CRP (mg/dL) 0.17 (0.06-0.38) 0.19 (0.10-0.50) 0.12
AIS A (N = 95) AIS B-D (N = 34) p value
WBC (/μL) 6000 (4750-6850) 5800 (4730-7130) 0.97
Neutrophil (/μL) 3490 (2540-4100) 3430 (2190-4180) 0.85
Lymphocyte (/μL) 1740 (1450-2070) 1880 (1410-2130) 0.41
CRP (mg/dL) 0.18 (0.08-0.47) 0.13 (0.03-0.39) 0.07

Data are presented as median (interquartile range). Laboratory findings were obtained from the first non-infectious episode for each patient. AIS, American Spinal Injury Association Impairment Scale; WBC, white blood cell; CRP, C-reactive protein.

3. Frequency of infection

Figure 1 shows the frequency of infection according to the neurological level and severity of injury. In the univariate analysis, there was no significant difference in the frequency of infection between the cervical and thoracolumbar SCI groups (Figure 1A). In contrast, the frequency of infection was significantly higher in the AIS A group than in the AIS B-D group (Figure 1B).

Figure 1. Frequency of infection according to neurological level of injury and injury severity.

Figure 1.

The frequency of infection was compared according to the neurological level of injury and injury severity using univariate analysis. There was no significant difference in the frequency of infection between the cervical and thoracolumbar SCI groups. In contrast, the frequency of infection was significantly higher in the AIS A group than in the AIS B-D group.

In addition, when infection frequency according to the neurological level of injury was compared after stratification by AIS, no significant difference was observed between cervical and thoracolumbar SCI in the AIS A group (45.8% [55/120] vs. 50.3% [82/163], p = 0.472). Similarly, in the AIS B-D group, there was no significant difference between cervical and thoracolumbar SCI (34.3% [23/67] vs. 25.0% [3/12], p = 0.741).

4. Multivariable analysis of factors associated with infection accounting for within-patient correlations

To assess the potential influence of repeated hospitalizations on the analysis, we first examined the association between a history of infection and the total number of hospitalizations per patient. Patients with a history of infection had significantly more hospitalizations than those without a history of infection (median 3 [2, 3, 4, 5] vs. 1 [1], p < 0.001).

Based on this finding, we performed multivariable analysis using generalized estimating equations (GEE), with patient ID as the clustering variable, to identify factors associated with infection while accounting for within-patient correlations arising from repeated hospitalizations (Figure 2). A longer time since SCI was significantly associated with lower odds of infection (OR 0.78 per 1-year increase, 95% CI 0.66-0.91, p = 0.0022). In contrast, AIS A (OR 1.43, 95% CI 0.77-2.64, p = 0.255), cervical SCI (OR 0.82, 95% CI 0.50-1.32, p = 0.409), age ≥65 years (OR 0.90, 95% CI 0.56-1.45, p = 0.666), male sex (OR 1.57, 95% CI 0.88-2.82, p = 0.130), and low BMI (OR 1.27, 95% CI 0.83-1.96, p = 0.276) were not significantly associated with infection.

Figure 2. Multivariable analysis of factors associated with infection.

Figure 2.

We performed a multivariable analysis using generalized estimating equations (GEE), with infection status as the dependent variable and injury severity, neurological level of injury, age ≥65 years, sex, time since SCI (per 1-year increase), and low BMI as explanatory variables, with patient ID as the clustering variable. A longer time since SCI was significantly associated with lower odds of infection. In contrast, AIS A status, neurological level of injury, age ≥65 years, male sex, and low BMI were not significantly associated with infection.

5. Immunological parameters in the prospective analysis

In the prospective immunological analysis, we evaluated nine episodes in seven patients with SCI. All episodes involved cervical SCI; five episodes were classified as AIS A and four as AIS B-D. Table 4 shows the results of the lymphocyte subset and serum cytokine analyses.

Table 4.

Patient characteristics and immunological parameters in the prospective immunological analysis.

Prospective episodes (N = 9)
Age, years 51 (47-67)
Sex, No. (%)
 Male 6 (67)
 Female 3 (33)
AIS grade, No. (%)
 A 5 (56)
 B-D 4 (44)
Level of injury, No. (%)
 Cervical 9 (100)
 Thoracolumbar 0 (0)
Time from SCI (days) 340 (240-530)
T cell (/μL) 1130 (870-1210)
Effector Th cell (/μL) 290 (210-350)
Effector Tc cell (/μL) 290 (250-380)
Treg cell (/μL) 44 (41-62)
NK cell (/μL) 130 (100-220)
B cell (/μL) 120 (100-130)
IL-6 (pg/mL) 7.9 (3.1-16.7)
IFN-γ (pg/mL) 0.25 (0.25-5.41)

Data are presented as median (interquartile range) or number (percentage). AIS, American Spinal Injury Association Impairment Scale; IFN-γ, interferon-γ; IL-6, interleukin-6; NK cell, natural killer cell; SCI, spinal cord injury; Tc cell, cytotoxic T cell; Th cell, helper T cell; Treg cell, regulatory T cell.

In two patients with both non-infectious and infectious episodes, we compared changes in immunological parameters within each patient as an exploratory analysis. During infection, the numbers of T cells, effector Tc cells, and effector Th cells tended to decrease in both patients (Figure 3A). In contrast, changes in Treg cells, B cells, NK cells, IFN-γ, and IL-6 varied between the two patients (Figure 3B).

Figure 3. Within-patient comparison of immunological parameters during non-infectious and infectious episodes.

Figure 3.

Immunological parameters during non-infectious and infectious episodes were compared within each of the two patients. The number of T cells, effector Tc cells, and effector Th cells tended to decrease during infection in both patients. In contrast, changes in Treg cells, B cells, NK cells, IFN-γ, and IL-6 were heterogeneous between the patients.

Discussion

In this study, we investigated the associations between infection occurrence, neurological level of injury, and injury severity in patients with SCI. We also evaluated the clinical factors associated with infection using multivariable analysis and examined changes in immunological parameters during infection as an exploratory analysis. In the retrospective analysis, infection frequency did not differ significantly between the cervical and thoracolumbar SCI groups. In contrast, the frequency of infection was significantly higher in the AIS A group than in the AIS B-D group. In the multivariable GEE analysis, a longer time since SCI was significantly associated with lower odds of infection (OR 0.78 per 1-year increase, 95% CI 0.66-0.91, p = 0.0022).

In contrast, AIS A, neurological level of injury, age ≥65 years, male sex, and low BMI were not significantly associated with infection. In addition, in a prospective immunological analysis of a small number of patients, T cells, effector Tc cells, and effector Th cells tended to decrease during infection in both patients. These findings suggest that clinical factors, including time since SCI, may be associated with the risk of infection in patients with SCI.

In SCI-IDS, immune dysfunction is thought to occur due to abnormalities in the sympathetic nervous and neuroendocrine systems, and the neurological level of injury and injury severity may influence the extent of this dysfunction. Therefore, these factors may be associated with infection risk [7]. In addition, the SCIentinel study suggested that immunosuppression after SCI might result from neurogenic changes that depend on the neurological level of injury and its severity [17]. Based on these findings, we examined the associations among the neurological level of injury, injury severity, and infection occurrence. Regarding the neurological level of injury, infection frequency did not differ significantly between cervical and thoracolumbar SCI, and the neurological level of injury was not significantly associated with infection occurrence in the multivariable GEE analysis. Furthermore, in analyses stratified by injury severity, infection frequency did not differ significantly between cervical and thoracolumbar SCI in either the AIS A or AIS B-D group.

Regarding injury severity, infection frequency was higher in the AIS A group than in the AIS B-D group in the univariate analysis. However, injury severity was not significantly associated with the occurrence of infection in the multivariable GEE analysis. Patients with AIS A exhibit severe motor and sensory impairments. These patients are more likely to have clinical conditions that may contribute to infection, such as impaired sputum clearance, difficulty in urinary management, pressure ulcer formation, and prolonged bed rest [18]. These findings suggest that the immunosuppression related to the neurological level of injury and injury severity, as proposed for SCI-IDS, may not be directly reflected in the occurrence of clinical infection.

In this study, a longer time since SCI was significantly associated with lower odds of infection. This finding suggests that the risk of infection after SCI may not be constant over time and may change from the acute to the chronic phase. During the acute and subacute phases, multiple risk factors for infection may coexist, including trauma, surgical stress, intensive care, catheter management, respiratory dysfunction, dysphagia, bed rest, and pressure ulcers [4, 18]. In addition, immunosuppression mediated by neuroendocrine changes and autonomic dysfunction may be prominent in the early phases of SCI [19]. In contrast, patients with a longer time since SCI may have more stable urinary and bowel management and pressure ulcer prevention. Therefore, the association between time since SCI and infection risk may involve not only immunological changes but also multiple clinical factors, such as complication management and adaptation to daily life.

In the present study, we observed no significant correlations between time since SCI and WBC, neutrophil, or lymphocyte counts during non-infectious episodes. However, simple changes in peripheral blood cell counts alone may not fully capture the immune abnormalities after SCI. The proposed mechanisms of SCI-IDS include abnormalities in the sympathetic nervous and neuroendocrine systems, changes in lymphocyte count and function, and abnormal bone marrow hematopoiesis [7]. In a mouse model of SCI, chronic bone marrow dysfunction accompanied by excessive proliferation and retention of hematopoietic stem and progenitor cells in the bone marrow has been reported, and this abnormality has been associated with enhanced CXCL12-CXCR4 signaling [8]. Based on these findings, peripheral blood cell counts alone may be insufficient for evaluating abnormalities in bone marrow hematopoiesis and changes in immune cell mobilization. Further studies are needed to assess the bone marrow hematopoietic dynamics and immune cell functions.

Although the sample size in the prospective immunological analysis was small, the numbers of T cells, effector Tc cells, and effector Th cells tended to decrease during infection. Previous studies have reported changes in peripheral T-cell subsets and impaired lymphocyte function in patients with SCI [13, 14, 20]. Although the limited number of cases warrants caution, these results suggest that immune responses during infection may be altered in patients with SCI. The infections in the two patients for whom non-infectious and infectious episodes were compared were pneumonia and urinary tract infection, respectively, and rapid antigen tests for both influenza and COVID-19 were negative in both patients. Therefore, the observed changes are unlikely to be attributable to lymphopenia associated with influenza or COVID-19 infection. However, it remains difficult to clearly distinguish the immunological changes caused by infection from those related to SCI-IDS.

In this study, IFN-γ and IL-6 changes differed between the two patients with both non-infectious and infectious episodes. Previous studies have reported increased levels of inflammatory markers such as IL-6 and CRP in patients with SCI [10], whereas other studies have suggested impaired immune responses [11]. Cytokine changes after SCI may, therefore, vary by patient background, time since SCI, and the presence or absence of infection. To understand immune responses during infection in patients with SCI, prospective and longitudinal analyses of immune dynamics, including changes in cytokine and lymphocyte subsets, are needed.

This study has several limitations. First, this was a single-center study, and patient backgrounds, reasons for hospitalization, and care systems may have influenced the results. Second, we performed a retrospective analysis on a per-hospitalization-episode basis and included multiple hospitalizations for the same patients. Although we accounted for within-patient correlations using GEE, patients with a history of infection had significantly more hospitalizations than those without, making it difficult to exclude the influence of differences in the number of hospitalizations. Third, we defined infection based on the attending physician's diagnosis in the medical records and the administration of antimicrobial agents rather than on unified prospective diagnostic criteria. Fourth, we could not fully adjust for factors associated with infection risk such as pressure ulcers, urinary management, respiratory function, nutritional status, comorbidities, and medications. Fifth, the prospective immunological analysis included only a small number of patients, all of whom had cervical SCI; therefore, it was insufficient to evaluate immunological differences according to neurological level of injury or injury severity. Thus, prospective immunological findings should be interpreted as hypothesis-generating.

Conclusion

In conclusion, this study showed that a longer time since SCI was associated with lower odds of infection in patients with SCI. In contrast, the neurological level of injury and injury severity were not independently associated with the occurrence of infection in the multivariable analysis. In a prospective immunological analysis of a small number of patients, T cells, effector Tc cells, and effector Th cells tended to decrease during infection. These findings suggest that infection risk after SCI may be influenced by multiple clinical factors, including time since SCI, and may also be associated with changes in immune cell dynamics. Further prospective studies stratified by neurological level of injury, injury severity, and time since SCI are needed to evaluate bone marrow hematopoietic dynamics and immune cell function, as well as peripheral blood immune profiles, and to clarify the association between changes in the immune and hematopoietic systems and the occurrence of infection.

Acknowledgements

This study was supported by a Japan Organization of Occupational Health and Safety Research Grant for the Promotion of Hospital Functions. The authors sincerely thank Dr. Yasunobu Murata for his valuable advice on preparing this manuscript.

References

  • 1. DeVivo MJ, Chen Y, Wen H.. Cause of death trends among persons with spinal cord injury in the United States: 1960-2017. Arch Phys Med Rehabil 2022; 103: 634-41. [DOI] [PubMed] [Google Scholar]
  • 2. Uchida R, Honda S, Suzuki K, et al.. The cause of death for patients with spinal cord injuries in the group of Rosai Hospitals in Japan. Jpn J Traumatol Occup Med 1999; 47: 175-81. Japanese. [Google Scholar]
  • 3. Uchida R, Sumida M, Tokuhiro A, Tanaka H, Murata K.. The mortality of spinal cord injured patients in the group of Rosai Hospitals in Japan. Jpn J Traumatol Occup Med 1999; 47: 431-6. Japanese. [Google Scholar]
  • 4. Garcia-Arguello LY, O'Horo JC, Farrell A, Blakney R, Sohail MR, Evans CT, et al.. Infections in the spinal cord-injured population. Spinal Cord 2017; 55: 526-34. [DOI] [PubMed] [Google Scholar]
  • 5. Held KS, Steward O, Blanc C, Lane TE.. Impaired immune responses following spinal cord injury lead to reduced ability to control viral infection. Exp Neurol 2010; 226: 242-53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Bracchi-Ricard V, Zha J, Smith A, Lopez-Rodriguez DM, Bethea JR, Andreansky S.. Chronic spinal cord injury attenuates influenza virus-specific antiviral immunity. J Neuroinflammation 2016; 13: 125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Jeffries MA, Tom VJ.. Peripheral immune dysfunction: a problem of central importance after spinal cord injury. Biology 2021; 10: 928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Carpenter RS, Marbourg JM, Brennan FH, Mifflin KA, Hall JCE, Jiang RR, et al.. Spinal cord injury causes chronic bone marrow failure. Nat Commun 2020; 11: 3702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Salomon J, Denys P, Merle C, Chartier-Kastler E, Perronne C, Gaillard JL, et al.. Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic programme with a 2 year follow-up-an observational prospective study. J Antimicrob Chemother 2006; 57: 784-8. [DOI] [PubMed] [Google Scholar]
  • 10. Davies AL, Hayes KC, Dekaban GA.. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1384-93. [DOI] [PubMed] [Google Scholar]
  • 11. Pavlicek D, Krebs J, Capossela S, Bertolo A, Engelhardt B, Pannek J, et al.. Immunosenescence in persons with spinal cord injury in relation to urinary tract infections - a cross-sectional study. Immun Ageing 2017; 14: 22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Riegger T, Conrad S, Liu K, Schluesener HJ, Adibzahdeh M, Schwab JM.. Immune depression syndrome following human spinal cord injury: a pilot study. Neuroscience 2009; 158: 1194-9. [DOI] [PubMed] [Google Scholar]
  • 13. Monahan R, Stein A, Gibbs K, Bank M, Bloom O.. Circulating T cell subsets are altered in individuals with chronic spinal cord injury. Immunol Res 2015; 63: 3-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Iversen PO, Hjeltnes N, Holm B, Flatebø T, Strøm-Gundersen I, Rønning W, et al.. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. Blood 2000; 96: 2081-3. [PubMed] [Google Scholar]
  • 15. Rupp R, Biering-Sørensen F, Burns SP, Graves DE, Guest J, Jones L, et al.. International Standards for Neurological Classification of Spinal Cord Injury: Revised 2019. Top Spinal Cord Inj Rehabil 2021; 27: 1-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Kanda Y.. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013; 48: 452-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kopp MA, Meisel C, Liebscher T, Watzlawick R, Cinelli P, Schweizerhof O, et al.. The spinal cord injury-induced immune deficiency syndrome: results of the SCIentinel study. Brain 2023; 146: 3500-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Gour-Provencal G, Mac-Thiong JM, Li A, Feldman DE, Parent S.. Decreasing pressure injuries and acute care length of stay in patients with traumatic spinal cord injury: a single-site quality improvement project. J Spinal Cord Med 2022; 45: 622-30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Pruss H, Tedeschi A, Thiriot A, Lynch L, Loughhead SM, Stutte S, et al.. Spinal cord injury-induced immunodeficiency is mediated by a sympathetic-neuroendocrine adrenal reflex. Nat Neurosci 2017; 20: 1549-59. [DOI] [PubMed] [Google Scholar]
  • 20. Haro S, Giron SH, Saenz A, Rojo D, Avendano-Ortiz J, Diaz D, et al.. Patients with chronic spinal cord injury display a severe and progressive CD4+ and CD8+ T lymphocyte compartment impairment. Int J Mol Sci 2023; 24: 17596. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Comprehensive Rehabilitation Science are provided here courtesy of Kaifukuki Rehabilitation Ward Association

RESOURCES